A3アデノシン受容体アゴニストであるナモデノソンの抗肥満効果
Pnina Fishman1, Inbal Itzhak2, Rifaat Safadi3
1Can-Fite BioPharma Ltd, Petah-Tikva, Israel. pnina@canfite.co.il.
International journal of obesity (2005)
|February 15, 2026
まとめ
A3アデノシン受容体アゴニストであるナモデノソンは,減量薬としての可能性を示しています. 臨床前研究では,アディポサイトの増殖と脂質の蓄積を抑制することが明らかになり,さらなる調査を支援しています.
科学分野:
- 薬理学 薬理学とは
- メタボリック疾患
- 細胞生物学 細胞生物学
背景:
- ナモデノソンは,肝臓疾患の臨床試験におけるA3アデノシン受容体 (A3AR) アゴニストです.
- 減量剤としてのその可能性は未知のものです.
研究 の 目的:
- 体重減少薬候補薬としてのナモデノソンの有効性を調査する.
- アディポサイト機能に対する効果と,ダイエット誘発の肥満モデルでの効果を評価する.
主な方法:
- 3T3-L1アディポサイトを使用して,増殖と脂質の蓄積を評価するインビトロ研究.
- 分子標的を決定するためのウエスタン・ブロット分析.
- ダイエット誘発肥満のマウスモデルを用いたin vivo研究.
主要な成果:
- ナモデノソンは,投与量に依存してアディポサイト増殖と脂質蓄積をin vitroで抑制した.
- 主要なアディポゲン系および炎症性マーカー (A3AR,PPARγ,C/EBPα,p-AKT,NF-kB) を低下させ,アディポネクチンを上昇させた.
- In vivoでは,ナモデノソンは脂肪が多いマウスの体重増加を著しく減少させましたが,痩せたマウスの体重増加は減少しませんでした.
結論:
- ナモデノソンは,肥満を軽減する臨床前効果を示しています.
- そのメカニズムは,脂肪細胞の分化と炎症経路の調節を伴う.
- 体重管理のためのナモデノソンに関するさらなる研究が必要である.
さらに関連する動画
13:09Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
Published on: July 31, 2021
4.1K
08:35Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.2K
関連する概念動画
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
01:30Adrenergic Agonists: Direct-Acting Agents
2.9K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.9K
01:31Adrenergic Receptors: ɑ Subtype
3.0K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.0K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
01:26Adrenergic Receptors: β Subtype
3.9K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.9K